Jonathan D Baghdadi1, Robert H Brook2,3, Daniel Z Uslan4, Jack Needleman5, Douglas S Bell6, William E Cunningham5,6, Mitchell D Wong6. 1. Department of Epidemiology and Public Health, University of Maryland, Baltimore. 2. RAND Corporation, Santa Monica, California. 3. David Geffen School of Medicine, UCLA (University of California, Los Angeles). 4. Division of Infectious Diseases, UCLA. 5. Department of Health Policy and Management, Fielding School of Public Health, UCLA. 6. Division of General Internal Medicine, UCLA.
Abstract
Importance: The Early Management Bundle for Severe Sepsis/Septic Shock (SEP-1) is a quality metric based on a care bundle for early sepsis management. Published evidence on the association of SEP-1 with mortality is mixed and largely excludes cases of hospital-onset sepsis. Objective: To assess the association of the SEP-1 bundle with mortality and organ dysfunction in cohorts with hospital-onset or community-onset sepsis. Design, Setting, and Participants: This retrospective cohort study used data from 4 University of California hospitals from October 1, 2014, to October 1, 2017. Adult inpatients with a diagnosis consistent with sepsis or disseminated infection and laboratory or vital signs meeting the Sepsis-3 (Third International Consensus Definitions for Sepsis and Septic Shock) criteria were divided into community-onset sepsis and hospital-onset sepsis cohorts based on whether time 0 of sepsis occurred after arrival in the emergency department or an inpatient area. Data were analyzed from April to October 2019. Additional analyses were performed from December 2019 to January 2020. Exposures: Administration of SEP-1 and 4 individual bundle components (serum lactate level testing, blood culture, broad-spectrum intravenous antibiotic treatment, and intravenous fluid treatment). Main Outcomes and Measures: The primary outcome was in-hospital mortality. The secondary outcome was days requiring vasopressor support, measured as vasopressor days. Results: Among the 6404 patient encounters identified (3535 men [55.2%]; mean [SD] age, 64.0 [18.2] years), 2296 patients (35.9%) had hospital-onset sepsis. Among 4108 patients (64.1%) with community-onset sepsis, serum lactate level testing within 3 hours of time 0 was associated with reduced mortality (absolute difference, -7.61%; 95% CI, -14.70% to -0.54%). Blood culture (absolute difference, -1.10 days; 95% CI, -1.85 to -0.34 days) and broad-spectrum intravenous antibiotic treatment (absolute difference, -0.62 days; 95% CI, -1.02 to -0.22 days) were associated with fewer vasopressor days. Among patients with hospital-onset sepsis, broad-spectrum intravenous antibiotic treatment was the only bundle component significantly associated with any improved outcome (mortality difference, -5.20%; 95% CI, -9.84% to -0.56%). Care that was adherent to the complete SEP-1 bundle was associated with increased vasopressor days in patients with community-onset sepsis (absolute difference, 0.31 days; 95% CI, 0.11-0.51 days) but was not significantly associated with reduced mortality in either cohort (absolute difference, -0.07%; 95% CI, -3.02% to 2.88% in community-onset; absolute difference, -0.42%; 95% CI, -6.77% to 5.93% in hospital-onset). Conclusions and Relevance: SEP-1-adherent care was not associated with improved outcomes of sepsis. Although multiple components of SEP-1 were associated with reduced mortality or decreased days of vasopressor therapy for patients who presented with sepsis in the emergency department, only broad-spectrum intravenous antibiotic treatment was associated with reduced mortality when time 0 occurred in an inpatient unit. Current sepsis quality metrics may need refinement.
Importance: The Early Management Bundle for Severe Sepsis/Septic Shock (SEP-1) is a quality metric based on a care bundle for early sepsis management. Published evidence on the association of SEP-1 with mortality is mixed and largely excludes cases of hospital-onset sepsis. Objective: To assess the association of the SEP-1 bundle with mortality and organ dysfunction in cohorts with hospital-onset or community-onset sepsis. Design, Setting, and Participants: This retrospective cohort study used data from 4 University of California hospitals from October 1, 2014, to October 1, 2017. Adult inpatients with a diagnosis consistent with sepsis or disseminated infection and laboratory or vital signs meeting the Sepsis-3 (Third International Consensus Definitions for Sepsis and Septic Shock) criteria were divided into community-onset sepsis and hospital-onset sepsis cohorts based on whether time 0 of sepsis occurred after arrival in the emergency department or an inpatient area. Data were analyzed from April to October 2019. Additional analyses were performed from December 2019 to January 2020. Exposures: Administration of SEP-1 and 4 individual bundle components (serum lactate level testing, blood culture, broad-spectrum intravenous antibiotic treatment, and intravenous fluid treatment). Main Outcomes and Measures: The primary outcome was in-hospital mortality. The secondary outcome was days requiring vasopressor support, measured as vasopressor days. Results: Among the 6404 patient encounters identified (3535 men [55.2%]; mean [SD] age, 64.0 [18.2] years), 2296 patients (35.9%) had hospital-onset sepsis. Among 4108 patients (64.1%) with community-onset sepsis, serum lactate level testing within 3 hours of time 0 was associated with reduced mortality (absolute difference, -7.61%; 95% CI, -14.70% to -0.54%). Blood culture (absolute difference, -1.10 days; 95% CI, -1.85 to -0.34 days) and broad-spectrum intravenous antibiotic treatment (absolute difference, -0.62 days; 95% CI, -1.02 to -0.22 days) were associated with fewer vasopressor days. Among patients with hospital-onset sepsis, broad-spectrum intravenous antibiotic treatment was the only bundle component significantly associated with any improved outcome (mortality difference, -5.20%; 95% CI, -9.84% to -0.56%). Care that was adherent to the complete SEP-1 bundle was associated with increased vasopressor days in patients with community-onset sepsis (absolute difference, 0.31 days; 95% CI, 0.11-0.51 days) but was not significantly associated with reduced mortality in either cohort (absolute difference, -0.07%; 95% CI, -3.02% to 2.88% in community-onset; absolute difference, -0.42%; 95% CI, -6.77% to 5.93% in hospital-onset). Conclusions and Relevance: SEP-1-adherent care was not associated with improved outcomes of sepsis. Although multiple components of SEP-1 were associated with reduced mortality or decreased days of vasopressor therapy for patients who presented with sepsis in the emergency department, only broad-spectrum intravenous antibiotic treatment was associated with reduced mortality when time 0 occurred in an inpatient unit. Current sepsis quality metrics may need refinement.
Authors: Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: Christopher W Seymour; Jason N Kennedy; Shu Wang; Chung-Chou H Chang; Corrine F Elliott; Zhongying Xu; Scott Berry; Gilles Clermont; Gregory Cooper; Hernando Gomez; David T Huang; John A Kellum; Qi Mi; Steven M Opal; Victor Talisa; Tom van der Poll; Shyam Visweswaran; Yoram Vodovotz; Jeremy C Weiss; Donald M Yealy; Sachin Yende; Derek C Angus Journal: JAMA Date: 2019-05-28 Impact factor: 56.272
Authors: Shannon A Novosad; Mathew R P Sapiano; Cheri Grigg; Jason Lake; Misha Robyn; Ghinwa Dumyati; Christina Felsen; Debra Blog; Elizabeth Dufort; Shelley Zansky; Kathryn Wiedeman; Lacey Avery; Raymund B Dantes; John A Jernigan; Shelley S Magill; Anthony Fiore; Lauren Epstein Journal: MMWR Morb Mortal Wkly Rep Date: 2016-08-26 Impact factor: 17.586
Authors: Chanu Rhee; Michael R Filbin; Anthony F Massaro; Amy L Bulger; Donna McEachern; Kathleen A Tobin; Barrett T Kitch; Bert Thurlo-Walsh; Aran Kadar; Alexandra Koffman; Anupam Pande; Yasir Hamad; David K Warren; Travis M Jones; Cara O'Brien; Deverick J Anderson; Rui Wang; Michael Klompas Journal: Crit Care Med Date: 2018-10 Impact factor: 7.598
Authors: Jeannie P Cimiotti; Edmund R Becker; Yin Li; Douglas M Sloane; Scott K Fridkin; Anna Beth West; Linda H Aiken Journal: JAMA Health Forum Date: 2022-05-27
Authors: Jennifer C Ginestra; Rachel Kohn; Rebecca A Hubbard; Andrew Crane-Droesch; Scott D Halpern; Meeta Prasad Kerlin; Gary E Weissman Journal: Ann Am Thorac Soc Date: 2022-09
Authors: J Jeffery Reeves; Natalie M Pageler; Elizabeth C Wick; Genevieve B Melton; Yu-Heng Gamaliel Tan; Brian J Clay; Christopher A Longhurst Journal: Yearb Med Inform Date: 2021-09-03